Drug Trial Radar · NCT03465722
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Last checked: Nov 20, 2026Latest source record: Oct 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
476
Actual
Start
Mar 26, 2018
Primary completion
Mar 9, 2020
Study completion Sep 15, 2021
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Mar 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.
Conditions
- GIST
Interventions
avapritinibDrug
Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
regorafenibDrug
Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Avapritinib Based on Progression-free Survival (PFS) Determined by Central Radiological Assessment Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST), Version 1.1Time frame: 24 Months
Locations
114 sites in 18 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Phoenix, Arizona
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California
University of Colorado Hospital
Aurora, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado
Washington Hospital Center - Oncology and Hematology
Washington D.C., District of Columbia
Mayo Clinic Cancer Center
Jacksonville, Florida
University of Miami
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Northside Hospital
Atlanta, Georgia
Northwestern Medicine
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Mayo Clinic Cancer Center
Rochester, Minnesota
Washington University in Saint Louis
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University
Columbus, Ohio
OHSU - Knight Cancer Institute
Portland, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
USO - Texas Oncology
Dallas, Texas
Texas Oncology - Denton South
Denton, Texas
University of Texas MD Anderson
Houston, Texas
Texas Oncology - Waco
Waco, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Summit Cancer Centers
Spokane, Washington
Medical College of Wisconsin - Froedtert Hospital
Milwaukee, Wisconsin
Flinders Medical Center
Adelaide, Australia
Monash Health
Clayton, Australia
The Canberra Hospital
Garran, Australia
AKH, Klinik f. Innere Med. I, Onkologie
Vienna, Austria
Institut Jules Bordet
Brussels, Belgium
Leuven Cancer Institute
Leuven, Belgium
Jewish General Hospital
Montreal, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
University Health Network
Toronto, Ontario, Canada
Beijing Cancer Hospital
Beijing, China
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.